cemsidomide (CFT7455) / C4 Therap - LARVOL DELTA

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: C4 Therapeutics, Inc.

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ASH 2024) - P1 | "Eligible MM pts must have received lenalidomide, pomalidomide, a proteasome inhibitor, and an anti-CD38 antibody. Dose escalation will continue until an MTD and/or the recommended phase 2 doses are identified. Updated data will be presented at the conference."

Clinical • First-in-human • P1 data • Anemia • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CRBN • IKZF1 • IKZF3

Identification of Ikaros As Novel Interaction Partner of Cyclin D1/CDK4 in MCL (ASH 2024) - "Knockdown of Ikaros and treatment with the Ikaros degrader lenalidomide and also the novel degrader CFT7455 induced apoptosis, G1-phase arrest and decreased CycD1 expression, indicating a direct effect of Ikaros on CycD1 levels. Our results indicate that Ikaros can transcriptionally regulate and stabilize CycD1, and in turn, CycD1-CDK4 may phosphorylate Ikaros and affect Ikaros transcriptional activity. This feedback loop may play an important role in the pathogenesis of MCL and could serve as a novel potential therapeutic target in MCL."

Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1 • CDK4 • IKZF1 • MYC

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, in Patients with Non-Hodgkin's Lymphoma (ASH 2024) - P1 | "Dose escalation will continue until an MTD and/or the recommended phase 2 doses are identified. Updated data will be presented at the conference."

Clinical • First-in-human • P1 data • Adult T-Cell Leukemia-Lymphoma • Anemia • B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CRBN • IKZF1 • IKZF3

Presented data analyzing population pharmacokinetic and exposure-response relationships for cemsidomide in MM and non-Hodgkin’s lymphoma (NHL) in a poster at the 2025 American Conference on Pharmacometrics (ACoP 2025). (GlobeNewswire) - "The analysis indicated an increased anti-myeloma effect at higher exposures and a clinically manageable exposure-safety relationship, supporting the risk-benefit analysis in heavily pre-treated MM patients...Completed dose escalation for the Phase 1 trial of cemsidomide in NHL...In peripheral T-cell lymphoma (PTCL), 9 out of 22 patients achieved a partial response or better with a PET-CT-based assessment."

P1 data • Trial status • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma

THIRD QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS (GlobeNewswire) - "Continued to execute operational steps necessary for the initiation of the Phase 2 MOMENTUM trial of cemsidomide in combination with dexamethasone in the fourth line or later for the first quarter of 2026 and the Phase 1b trial of cemsidomide in combination with elranatamab in the second line or later for the second quarter of 2026."

New P1 trial • New P2 trial • Multiple Myeloma

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering (GlobeNewswire) - "$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab."

Financing • New P1 trial • Multiple Myeloma

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma (GlobeNewswire) - "Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial.... This Phase 1b trial, which is expected to initiate in Q2 2026, will seek to establish an optimal dose for cemsidomide in combination with elranatamab. Under the terms of the agreement, Pfizer will supply elranatamab at no cost while C4T will sponsor and conduct the trial."

Commercial • New P2 trial • Multiple Myeloma

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2025) - P1 | "MM eligible pts must have received lenalidomide, pomalidomide, a proteasome inhibitor, and an anti-CD38 antibody. Cemsidomide with DEX demonstrates compelling efficacy and tolerability as an all-oral therapy in a heavily pre-treated RRMM population, the majority of whom had received a CAR-T or bispecific antibody. Grade 3-4 toxicities consist largely of cycle 1-2 myelosuppression, which has been manageable with limited dose reductions and discontinuations. 100 ug is the maximum administered dose for planned further development."

Clinical • First-in-human • P1 data • Anemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • CRBN • IKZF1 • IKZF3

Cemsidomide’s Regulatory Path (GlobeNewswire) - "Fourth line of therapy or later: C4T expects to initiate a Phase 2 single-arm registrational trial in the first quarter of 2026 to evaluate cemsidomide in combination with dexamethasone; initial ORR data is expected in the second half of 2027....Second line of therapy or later: C4T plans to initiate a Phase 1b trial in the second quarter of 2026 to evaluate the safety and tolerability of cemsidomide and dexamethasone in combination with a BCMA BiTE; data are expected by mid-2027."

Clinical data • New P1 trial • New P2 trial • Multiple Myeloma

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting (GlobeNewswire) - "As of the data cutoff date, 72 patients were evaluable for safety; Cemsidomide was generally well tolerated with manageable incidents of on-target neutropenia across all dose levels; there were low rates of febrile neutropenia across all dose levels: three patients (4%) at Grade 3, one patient (1%) at Grade 4 and no patients at Grade 5...Cemsidomide achieved >50% degradation of IKZF1 and > 80% degradation of IKZF3, as assessed by mass spectrometry in human peripheral blood mononuclear cells (PBMCs)....Across all dose levels, 23 patients (34%); achieved a partial response (PR) or better, with a median duration of response of 9.3 months. At the 100 μg dose level, seven patients (50%) achieved a PR or better."

P1 data • Multiple Myeloma

CFT7455-1101: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (clinicaltrials.gov) - P1 | N=224 | Active, not recruiting | Sponsor: C4 Therapeutics, Inc. | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2025 | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P1

Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • TNFRSF8

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting (Yahoo Finance)

P1 data • Multiple Myeloma

KEY UPCOMING MILESTONES AND DATA PRESENTATIONS (GlobeNewswire) - "By year-end 2025, C4T expects to align with the FDA on a recommended Phase 2 dose based on the existing Phase 1 MM data....Present data from full cemsidomide Phase 1 dose escalation in MM at IMS taking place from September 17 – September 20, 2025...Present data from cemsidomide Phase 1 dose escalation in NHL in Q4 2025; Enable initiation of the next phase of cemsidomide clinical development in MM with new studies expected to initiate in early 2026; Present poster analyzing cemsidomide clinical data of population pharmacokinetic and exposure-response relationships in MM and NHL at the 2025 American Conference on Pharmacometrics (ACoP 2025) on October 20, 2025."

New trial • P1 data • Trial status • Multiple Myeloma • Non-Hodgkin’s Lymphoma

SECOND QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS (GlobeNewswire) - P1/2 | N=224 | NCT04756726 | Sponsor: C4 Therapeutics, Inc. | "Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level...Completed enrollment and dose escalation for the Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s Lymphoma (NHL). Cemsidomide continued to demonstrate a well-tolerated profile and compelling response rates in MM and NHL."

P1 data • Multiple Myeloma • Non-Hodgkin’s Lymphoma

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) - "KEY UPCOMING MILESTONES: Present data from completed cemsidomide Phase 1 dose escalation in MM in Q3 2025; Complete cemsidomide Phase 1 dose escalation in NHL and present data in Q4 2025; Open expansion cohort(s) in PTCL as part of the current cemsidomide Phase 1/2 trial in the second half of 2025; Enable initiation of the next phase of clinical development for cemsidomide with new studies expected to initiate in early 2026."

New trial • P1 data • Trial status • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma

Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024. (PubMed, J Hematol Oncol) - "Currently, the main categories developed based on degraders include molecular glue (such as Cemsidomide, NX-5948), PROTACs (such as BGB-16673, AC-676, KT-333 ), and RNA degraders (such as SKY-1214). This correspondence summarizes the preclinical and clinical updates on degrader therapies presented at the ASH 2024 annual meeting."

Journal • Review • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - "KEY UPCOMING MILESTONES: Cemsidomide: Complete Phase 1 dose escalation and present data in MM and NHL in the second half of 2025; Open expansion cohort(s) in PTCL as part of the current Phase 1/2 trial in the second half of 2025; Enable initiation of the next phase of clinical development for MM and PTCL, with new studies expected to initiate in early 2026."

P1 data • Trial status • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology (GlobeNewswire) - "Cemsidomide - Multiple Myeloma: Enable initiation of the next phase of clinical development to investigate cemsidomide in combination with dexamethasone in the late-line setting, and in combination with other MM agents for earlier lines of treatment. These new studies are expected to initiate in early 2026. Complete Phase 1 dose escalation and present data in the second half of 2025. Non-Hodgkin’s Lymphoma: Complete Phase 1 dose escalation and present data in the second half of 2025. Open expansion cohort(s) of the current Phase 1/2 trial in patients with peripheral T-cell lymphoma (PTCL) in the second half of 2025. Enable initiation of the next phase of clinical development to investigate cemsidomide monotherapy in later lines of therapy in PTCL. This new study is expected to initiate in early 2026."

New trial • P1 data • Trial status • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma

C4T has identified the…next steps in cemsidomide MM development (GlobeNewswire) - "Complete Phase 1 dose escalation trial in MM to establish go forward doses; Initiate initial combination trials; Engage regulatory authorities on registrational path."

Trial status • Multiple Myeloma

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader (GlobeNewswire) - P1/2 | N=224 | NCT04756726 | Sponsor: C4 Therapeutics, Inc. | "Anti-lymphoma activity: Cemsidomide monotherapy demonstrated anti-lymphoma activity across a broad range of doses. As of the data cutoff, 21 patients were evaluable for efficacy, 16 of which had PTCL. Cemsidomide displays a differentiated pharmacokinetic profile with an approximate two-day half-life and an ability to induce rapid and potent degradation of IKZF1/3. Across all dose levels explored, cemsidomide achieved a 38 percent ORR and 19 percent CMR rate. In patients with PTCL, cemsidomide achieved a 44 percent ORR and 25 percent CMR rate."

P1 data • Non-Hodgkin’s Lymphoma

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader (GlobeNewswire) - P1/2 | N=224 | NCT04756726 | Sponsor: C4 Therapeutics, Inc. | "Anti-myeloma activity: Cemsidomide in combination with dexamethasone demonstrated anti-myeloma activity across a broad range of doses, highlighting a wide therapeutic range. As of the data cutoff, 42 patients were evaluable for anti-myeloma activity. Across all dose levels, cemsidomide in combination with dexamethasone achieved a 26 percent ORR and a 40 percent clinical benefit rate (CBR). At the highest dose level explored to date (75 µg QD), cemsidomide achieved a 36 percent ORR and a 45 percent CBR. At the two highest dose levels evaluated to date (62.5 µg QD and 75 µg QD), 62 percent of patients remained on therapy as of the data cutoff date."

P1 data • Multiple Myeloma

Next-Generation Novel Therapies in Multiple Myeloma (ICBMT 2024) - "A wealth of therapeutic options have been approved for the treatment of newly diagnosed (ND) and relapsed/refractory (RR) multiple myeloma (MM) over the past two decades, with proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (IMiDs; thalidomide, lenalidomide, pomalidomide), and monoclonal antibodies (mAbs; including the CD38 mAbs daratumumab and isatuximab, as well as the SLAMF7-targeting mAb elotuzumab) currently forming the backbone of treatment approaches in each setting. Additional targeted therapies have further enhanced the armamentarium, including, previously, the histone deacetylase inhibitor panobinostat, and, more recently, the nuclear export inhibitor selinexor 1 and the peptide–drug conjugate (PDC) melflufen. 2,3 Furthermore, novel immune-based treatment options such as the antibody–drug conjugate (ADC) belantamab mafodotin, the BCMA-targeting CAR T-cell therapies idecabta-gene vicleucel (ide-cel) and ciltacabtagene autoleucel..."

Hematological Malignancies • Multiple Myeloma • Oncology • Targeted Protein Degradation • CRBN • IRF4 • SLAMF7

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "C4 Therapeutics, Inc...today announced that two abstracts from the ongoing Phase 1/2 trial of cemsidomide have been accepted for presentation at the ASH Annual Meeting taking place from December 7 – 10, 2024 in San Diego, California. Non-Hodgkin’s lymphoma (NHL) data will be shared as an oral presentation and multiple myeloma (MM) data will be shared as a poster presentation."

P1/2 data • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - "Cemsidomide: Present updated dose escalation and expansion cohort data from the 50 µg M/W/F, 37.5 µg QD, 62.5 µg QD, and 75 µg QD dose levels in approximately 40 patients from the ongoing Phase 1/2 clinical trial with dexamethasone in R/R MM at the ASH Annual Meeting in December 2024; Present dose escalation data from the 25 µg M/W/F, 50 µg M/W/F, 37.5 µg QD, 62.5 µg QD, and 100 µg QD dose levels in approximately 25 patients from the ongoing monotherapy Phase 1/2 clinical trial in R/R NHL at the ASH Annual Meeting in December 2024; Complete Phase 1 dose exploration in R/R MM and R/R NHL by year-end."

P1/2 data • Trial status • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology